Abstract 4211
Background
To analyze patterns of failure for patients with LA-NSCLC receiving definitive chemoradiotherapy and build a nomogram for predicting the failure patterns in these patients.
Methods
Clinicopathological materials of patients between 2013 and 2016 with LA-NSCLC receiving definitive chemoradiotherapy and following-up in our hospital were collected. The endpoint was the first failure after definitive chemoradiotherapy. Based on logistic regression, the predictive value of each factor was evaluated and nomogram was built. This model was validated by ROC curve, calibration curve and decision curve analysis (DCA).
Results
With a median follow-up of 28 month, 100 patients were observed failure. Local failure and distant failure were 46 and 54, respectively. Univariate and multivariate analysis indicated that younger (p = 0.016, OR (95%CI): 0.936 (0.887-0.987)), peripheral NSCLC (p = 0.025, OR (95%CI): 2.732 (1.137-6.567)) and epidermal growth factor receptor (EGFR) mutant (p = 0.020, OR (95%CI): 3.747 (1.234-11.381)) were independent predictors of distant failure, which were included in the nomogram. ROC curve showed that area under the ROC curve (AUC) of the nomogram was 0.713, which was better than any factors along. Calibration curve revealed a satisfactory consistency between the predicted distant failure and actual observation. DCA showed most of the threshold probabilities in this model were with good net benefits.
Conclusions
We concluded that age, tumor location and EGFR mutation status could predict failure patterns in patients with LA-NSCLC receiving definitive chemoradiotherapy. A nomogram was built and validated based on these factors, showing a potential predictive value in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract